Repligen (RGEN)

Even a vaccine that's 50% effective with some side effects would be a game changer. The Trump Administration is throwing billions into that hope and investors are seeing big profits.

3 Great Growth Stocks That Kept Climbing in This Tough Market

By Louis Navellier, Editor, Growth Investor Jun 22, 2020

While many companies were unable to avoid the wrath of the coronavirus pandemic, these three companies stood out as big winners.

7 Pharmaceutical Stocks to Buy for Post-Pandemic Gains

By Louis Navellier and the InvestorPlace Research Staff Jun 9, 2020

Much of the conversation about pharmaceutical stocks rests on the coronavirus, but these high-growth names have potential beyond the pandemic.

Repligen Stock Could See Significant Upside With Coming ETF Realignment

By Louis Navellier, Editor, Growth Investor Jun 8, 2020

Smart beta ETFs typically rebalance every 90 days. The next big rebalance will come in the next few weeks and likely push healthcare stock Repligen (RGEN) higher.

3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector

By Louis Navellier, Editor, Growth Investor Sep 14, 2019

When rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed...some fairly, and some not (as we’ll see).

7 Top-Rated Biotech Stocks to Invest In Today

By Louis Navellier, Editor, Growth Investor Jun 14, 2019

Despite the trade dispute with China, these biotech stocks each earn top marks in Portfolio Grader for fundamentals, earnings and momentum.

This Medical Device Company is Outperforming the Rest of the Sector

By Ken Trester Jun 3, 2019

This morning, I am recommending a bullish trade on Repligen Corporation (NASDAQ:RGEN), the bioprocessing company.

5 Pharma Stocks to Stay Away From

By Will Healy, InvestorPlace Contributor Nov 12, 2018

With an aging population, pharma stocks can be a very profitable investments. These 5 biotechs probably aren't.

Trade of the Day: Repligen (NASDAQ:RGEN)

By InvestorPlace Research Staff May 5, 2017

Investors are in for a wild ride later this week as Under Armour prepares to report its first-quarter earnings results before the open on Thursday.

37 Biotechnology Stocks to Sell Now

By Portfolio Grader Dec 26, 2016

This week, the overall grades of 37 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

Hottest Manufacturing Stocks Now – RDUS ATRA RARE CMCO

By Portfolio Grader Nov 24, 2016

The following stocks were moving the Manufacturing sector today.

21 Biotechnology Stocks to Buy Now

By Portfolio Grader Oct 17, 2016

This week, 21 Biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").